5 252

Cited 10 times in

Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency

Authors
 Jin Soon Hwang  ;  Hae Sang Lee  ;  Woo Yeong Chung  ;  Heon-Seok Han  ;  Dong-Kyu Jin  ;  Ho-Seong Kim  ;  Cheol-Woo Ko  ;  Byung-Churl Lee  ;  Dae-Yeol Lee  ;  Kee-Hyoung Lee  ;  Jeh-Hoon Shin  ;  Byung-Kyu Suh  ;  Han-Wook Yoo  ;  Hyi-Jeong Ji  ;  Jin-Hwa Lee  ;  Yoon Ju Bae  ;  Duk-Hee Kim  ;  Sei Won Yang 
Citation
 EUROPEAN JOURNAL OF ENDOCRINOLOGY, Vol.169(2) : 179-185, 2013 
Journal Title
 EUROPEAN JOURNAL OF ENDOCRINOLOGY 
ISSN
 0804-4643 
Issue Date
2013
Abstract
PURPOSE: The purpose of this study was to investigate the efficacy and safety of LB03002, a sustained-release human GH (SR-hGH), compared with that of daily rhGH for 12 months in children with GH deficiency (GHD). METHODS: A total of 73 children with GHD were screened and 63 eligible subjects were randomized in a 1:1 ratio of LB03002 (SR-hGH) to daily rhGH treatment group. LB03002 was administered once weekly at a dose of 0.5 mg/kg while daily rhGH was administered for 6 consecutive days with equally divided doses to make a total of 0.21 mg/kg per week. Treatments were given for 12 months by s.c. injections. Injection site reactions and adverse events were investigated throughout the study period. RESULTS: The mean (S.D.) height velocity (HV) SHOWED a clinically significant increase after the 6-month treatment: 3.00 (1.15) cm/year at screening to 9.78 (1.98) cm/year at 6 months in the LB03002 group; 2.39 (1.63) cm/year at screening to 10.56 (2.65) cm/year at 6 months in the daily rhGH group. The increased HV at 12 months was still maintained in both the groups: 9.06 (1.63) cm/year at 12 months in the LB03002 group; 9.72 (2.32) cm/year at 12 months in the daily rhGH group. Most of the adverse drug reactions were mild and tolerable. No subjects were withdrawn due to adverse events. CONCLUSION: Weekly injection of LB03002 at a dose of 0.5 mg/kg per week was confirmed to have comparable efficacy to daily injection of rhGH at a dose of 0.21 mg/kg per week. Both formulations were well tolerated.
Full Text
http://eje-online.org/content/169/2/179.long
DOI
10.1530/EJE-13-0148
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Ho Seong(김호성) ORCID logo https://orcid.org/0000-0003-1135-099X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/88438
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links